Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical PBSCT with Post-Transplant Cyclophosphamide for Hematologic Malignancies
NCT00782379Phase 2Completed
- Sponsor
- Northside Hospital
- Start
- Oct 2008
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in leukemia, lymphoma and myelodysplastic syndrome (MDS), sponsored by Northside Hospital. Primary endpoints: Incidence of Graft Rejection at 100 days and Incidence of Severe Graft-versus-host Disease at 100 days. Started Oct 2008; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
leukemialymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00782379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782379.